CAPR Stock Eyes 1st Weekly Gain In 5 Weeks: Capricor’s DMD Therapy Faces FDA Panel Review Next Week, Retail Sees ‘Excellent Opportunity’
The Food and Drug Administration’s Advisory Committee is scheduled to meet on July 29 to review Capricor’s Biologics License Application for Deramiocel. The FDA has set a Prescription Drug User Fee Act target action date of Aug. 22, 2026. The application is backed by data from the Phase 2 Hope-2 trial and the Phase 3 … Read more